Navigation Links
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Date:11/11/2008

darone showed a low risk of pro-arrhythmia and no excess of hospitalizations for congestive heart failure. There was a similar rate of study drug discontinuation between the 2 study groups.

About Atrial Fibrillation

Atrial fibrillation (AF) is a common heart arrhythmia in which the upper chambers of the heart beat in an uncoordinated and disorganised fashion, which can cause palpitations, shortness of breath and fatigue. Atrial fibrillation (AF) currently represents a major economic burden for society(3). 70 percent of the annual cost of AF management is driven by inpatient care and interventional procedures(4). Hospitalizations for AF have increased dramatically (2- to 3-fold) in recent years(5). AF hospitalizations now represent a third of all hospitalizations for arrhythmia and mortality. AF affects nearly seven million people in the European Union and the United States(6).

The condition is increasingly frequent with advancing age and is often caused by age-related changes in the heart or as a result of cardiovascular disease. AF increases the risk of stroke five-fold and heart failure two- to three-fold. AF also doubles the risk of mortality and is an independent risk factor for sudden cardiac death.

Without appropriate management, AF can lead to serious complications such as stroke and congestive heart failure. In addition to preventing stroke and reducing the burden of the disease, successful management of AF should also aim at further reducing CV morbidity and mortality(7).

The aims of treatment for patients with AF are related to managing the arrhythmia itself and to the prevention of thromboembolism (obstruction of a blood vessel caused by fragments of a blood clot carried from the site of origin to obstruct another vessel). Atrial fibrillation may be treated with medications which either slow the heart rate or revert the heart rhythm back to normal.

About the ATHENA Study

The landmark ATHENA study is the onl
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Highlights from Avanafil Development Program Include: ... trials Comparative in-vitro selectivity of avanafil, sildenafil, ... post-prostatectomy population VIVUS, Inc. (NASDAQ: ... presented at the Sexual Medicine Society of North America (SMSNA) ...
... Campden Publishing Ltd today launched its medical and educational ... with the launch, Campden Health Communications has separately announced ... that enables its readers to upload video content directly ... magazine image. This is the first time the ,Aurasma, ...
Cached Medicine Technology:Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 2Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 3Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 4Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 5Campden Publishing Unveils new Med Comms Division and World-First Technology Licence 2
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Newest and Largest Hope Lodge in,New York City, NEW ... challenges. Finding an affordable, supportive place to stay,during treatment shouldn,t ... and largest Hope Lodge in the nation: the Hope Lodge,New ... steps from Penn Station at 132 W. 32 St., the ...
... Compendium Helps to Assure the Safety and Purity ... ... Pharmacopeia (USP),today announced the release of the latest edition of the ... quality and,purity of ingredients found in foods consumed by the public ...
... a five-year, $20.5 million grant from the Bill & ... the biological factors underlying immune system control of HIV, ... support to the International HIV Controllers Study, which currently ... has the overall goal of discovering information that can ...
... Needs, WASHINGTON, March 4 To meet increased ... from,the Global War on Terror, the Department of Veterans ... "Not all the wounds of war are visible," said ... committed to ensuring veterans receive,world-class care for mental health ...
... a significant improvement in their quality of life, ... research published in the March 2008 issue of ... German study evaluated the quality of life of ... Implant Questionnaire (NCIQ), a self-administered assessment that asks ...
... of genetic material between two closely related strains of ... and 1951 human flu epidemics, according to biologists. The ... pandemics and others lead to seasonal epidemics., Until now, it ... viruses swap genes with influenza viruses that infect birds ...
Cached Medicine News:Health News:American Cancer Society to Open Doors to Its New Free Lodging and Support Center in NYC for Cancer Patients and Caregivers 2Health News:U.S. Pharmacopeia Releases New Edition of the Food Chemicals Codex 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 3Health News:VA to Train More Psychologists 2Health News:Study uncovers cause of flu epidemics 2Health News:Study uncovers cause of flu epidemics 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: